GlassScriptPhysician profile
Maya Aji
NPI 1841904364
$5,580.02
in general payments reported to CMS, 2019-2025
30 companies · $2,373 in 2025
The $2,373 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,124 · 2024: $2,083 · 2025: $2,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,480 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,480.03 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,142.15 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $919.75 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $479.81 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $365.00 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Mallinckrodt Hospital Products INC. | $334.44 | 2023-2025 | Acthar |
| Aop Health US, LLC | $271.71 | 2025 | Rapiblyk |
| Baxter Healthcare | $225.07 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Grifols USA, LLC | $212.20 | 2023-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $156.64 | 2023-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $148.26 | 2024-2025 | Glassia |
| Lilly USA, LLC | $147.44 | 2025 | Zepbound |
| Viatris Specialty LLC | $146.73 | 2025 | Yupelri |
| Electromed, INC. | $140.30 | 2023-2025 | Smartvest |
| United Therapeutics Corporation | $115.21 | 2024-2025 | Tyvaso, Tyvaso |
| Janssen Pharmaceuticals, INC | $100.49 | 2023-2024 | Xarelto |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.07 | 2023-2025 | Ofev, Jascayd |
| Ani Pharmaceuticals, INC. | $78.82 | 2024-2025 | Purified Cortrophin Gel |
| Abbvie INC. | $77.11 | 2023-2025 | Teflaro, Avycaz |
| Mylan Specialty L.P. | $67.80 | 2024 | Yupelri |
| Insmed, INC. | $66.05 | 2024-2025 | Arikayce |
| Philips North America LLC | $57.73 | 2023-2024 | (Ak6) Vest Therapy |
| Actelion Pharmaceuticals US, INC. | $44.57 | 2024 | Opsumit, Uptravi |
| Inogen, INC. | $28.72 | 2025 | |
| Liquidia Technologies, INC. | $28.54 | 2025 | Yutrepia |
| Optinose US, INC. | $28.28 | 2024 | |
| Pfizer INC. | $27.33 | 2023 | |
| Tactile Systems Technology INC | $20.24 | 2024 | Flexitouch Plus, Entre Plus |
| Inspire Medical Systems, INC. | $19.38 | 2023 | Inspire |
| Breas Medical, INC. | $16.04 | 2025 | Vivo 45 Ls |
| Amgen INC. | $14.14 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Aji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.